| Literature DB >> 31778432 |
Giovana Vesentini1, Regina El Dib2,3, Leonardo Augusto Rachele Righesso4, Fernanda Piculo1, Gabriela Marini1,5, Guilherme Augusto Rago Ferraz1, Iracema de Mattos Paranhos Calderon1, Angélica Mércia Pascon Barbosa6, Marilza Vieira Cunha Rudge1.
Abstract
There is an ongoing discussion regarding abdominal muscle (AbM) and pelvic floor muscle (PFM) synergism. Therefore, this study aimed to investigate the cocontraction between AbMs and PFMs in women with or without pelvic floor dysfunction (PFD). The following databases were searched up to December 21, 2018: MEDLINE, EMBASE, LILACS, PEDro and CENTRAL. We included any study that assessed the cocontraction between PFMs and AbMs in women with and without PFD. Two reviewers independently screened eligible articles and extracted data. The outcomes were extracted and analyzed as continuous variables with random effect models. Twenty studies were included. A meta-analysis did not show differences in women with and without PFD. However, a sensitivity analysis suggested cocontraction of the transversus abdominis (TrA) during PFM contraction in healthy women (standardized mean difference (SMD) -1.02 [95% confidence interval (CI) -1.90 to -0.14], P=0.02; I2= not applicable; very low quality of evidence). Women with PFD during contraction of PFMs showed cocontraction of the obliquus internus (OI) (SMD 1.10 [95% CI 0.27 to 1.94], P=0.01; I2= not applicable; very low quality of evidence), and obliquus externus (OE) (SMD 2.08 [95% CI 1.10 to 3.06], P<0.0001; I2 = not applicable; very low quality of evidence). Increased cocontraction of the TrA may be associated with maximal contraction of PFMs in women without PFD. On the other hand, there is likely an increased cocontraction with the OI and OE in women with PFD.Entities:
Mesh:
Year: 2019 PMID: 31778432 PMCID: PMC6862713 DOI: 10.6061/clinics/2019/e1319
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1Flowchart of the studies included in this review.
Study characteristics related to the study design, location, number of participants, mean age, and inclusion and exclusion criteria.
| Author | Study design | Location | No. participants | Mean age | Inclusion criteria | Exclusion criteria |
|---|---|---|---|---|---|---|
|
| ||||||
| Bø et al. (27) | Cross-sectional | Europe | 13 | 46.5 | Consecutive women, at their first consultation in an ongoing randomized clinical trial on PFMT to reduce POP | Inability to understand the Norwegian language and contract the PFMs; nulliparous or less than 12 m pp; previous pelvic surgery; chronic lung disease, or stage 0 and 4 POP measured by the POP quantified |
| Tajiri et al. (22) | Randomized control trial | Asia | 15 | 52 | Women who had experienced one or more SUI events in the last 1 m | NR |
|
| ||||||
| Bø et al. (26) | Cross-sectional | Europe | 3 | 31.6 | Physical therapists; aged 30-33 y; extensive experience in correct PFM contractions | NR |
| Bø et al. (25) | Cross-sectional | Europe | 6 | 19.5 | Women aged 19-21 y; nulliparous; no history of UI, neurological disease, or urinary tract infection; exercising regularly more than 3×/week | NR |
| Sapsford et al. (6) | Cross-sectional | Australia | 7 | 49.3 | Parous women with a history of vaginal deliveries | History of PFD or LBP; abdominal or pelvic surgery; neurological or respiratory condition; regularly performing sit-ups or AbM training |
| Neumann et al. (33) | Cross-sectional | Australia | 4 | 34 | Nulliparous women aged 25-42 y, who were tested on two occasions 1 week apart | Skinfold thickness of >2.5 cm; history of LBP; known or suspected pregnancy; UI; urinary tract or vaginal infection; surgery involving incision of the left abdominal wall |
| Madill et al. (9) | Cross-sectional | Canada | 15 | 36.3 | Continent women aged 21- 60 y; not pregnant; had not given birth in the previous 12 months; in good general health | History of DM, neurological conditions, or autoimmune CT disorders; used any medications to treat or known to exacerbate UI; previous history of SUI |
| Thompson et al. (37) | Cross-sectional | Australia | 13 | 37 | Women aged 20-55 y and premenopausal or on HRT and consistent PFM exercise technique | History of urinary tract or vaginal infection; known or suspected pregnancy; surgery involving incision of the abdominal wall; obesity; history of LBP or sporting activities; neurological disorders; inability to understand English |
| Madill et al. (32) | Cross-sectional | Canada | 15 | 36.3 | Women aged 21-60 y; no history of SUI; not pregnant or had not given birth in the previous 12 m and in good general health | History of DM; neurological conditions; autoimmune CT disorders; used any medications to treat or known to exacerbate UI; history of SUI |
| Junginger et al. (30) | Cross-sectional | NR | 9 | 42 | Volunteers without PFM disorders; aged 32-59 y; with height of 157-174 cm and weight of 57-72 kg | History of LBP; hip or abdominal surgery or history of PFD and of laparotomy |
| Strupp et al. (35) | Cross-sectional | Central and South America | 34 | 28.1 | Willingness to participate in the study and ability to contract the PFM and perform the AHT correctly | Unable to contract AbM and PFM correctly; pregnancy; neurological disease; autoimmune CT disorder or PFD |
| Chmielewska et al. (28) | Cross-sectional | Europe | 19 | 23.6 | Continent women aged 19-28 y | SUI; pregnancy; childbirth(s); pelvic surgery; DM; hypertension; neurological abnormalities; urinary tract infection; elevated temperature; practicing a professional sport; spinal pain; obesity |
| Silva et al. (23) | Prospective | Central and South America | 25 | 24.76 | Women aged 18-35 y; no history of UI | Virgin women; abdominal-pelvic surgeries; metabolic disorders; presence of myopathies and collagen diseases, neurological disorders, cognitive disturbance and physical limitations; previous PFM training; inability to contract PFM |
| Ithamar et al. (39) | Cross-sectional | Central and South America | 30 | 25.77 | women aged 18-35 y; BMI between 18.50-24.99 kg/m2; abdominal skinfold ≤3 cm; with active or irregularly active physical activity | Abdominal or pelvic surgery; pregnancy; metabolic disorders; smoking; neurological; respiratory or cardiac disease; PFD or menstrual dysfunctions |
|
| ||||||
| Devreese et al. (29) | Cross-sectional | Europe | C: 40 I: 40 | C: 50.9 I: 48.4 | Patients were referred by the hospital for an individual pelvic floor exercise program | Subjects with a vaginal, urethral, or bladder infection, neurological disorders, LBP or pregnancy |
| Thompson et al. (38) | Cross-sectional | Australia | C: 13 I: 13 | C: 37 I: 38 | Inclusion criteria for both groups were women aged 20-55 y, premenopausal or on HRT, and using a consistent PFM exercise technique | History of urinary tract or vaginal infection; known or suspected pregnancy; surgery involving incision of the abdominal wall; obesity; history of LBP or sporting activities; neurological disorders; inability to understand English |
| Madill et al. (31) | Cross-sectional | Canada | C: 28 I: 44 | C: 46.8 I: 49.65 | C and SUI women aged 21-60 y; not pregnant and not given birth in the last 12 m; in good general health. | Previous gynecological or continence surgery, POP greater than stage 2; intrinsic sphincter deficiency; history of DM; neurological conditions; autoimmune CT disorders; use of any medications to treat or known to exacerbate UI |
| Arab et al. (24) | Cross-sectional | Asia | C: 10 I: 10 | C: 41.66 I: 38.47 | Women who had UI, were premenopausal, or were on HRT. Asymptomatic females, matched in age and body mass index and with no symptoms of UI. | Pregnancy and parturition in the previous 12 m; neurological or respiratory disorders; severe LBP; POP greater than stage 2; surgery of the abdominal or pelvic regions |
| Tajiri (36) | Cross-sectional | Asia | C: 25I: 7 | C: 45.8 I: 50.1 | Primiparous women | Not reported |
| Ptaszkowski et al. (34) | Cross-sectional | Europe | C: 14 I: 16 | C: 66.1 I: 63.9 | Control group: no history of SUI; UI group: history of SUI. | Inability to contract the PFMs; previous gynecological and abdominal surgery; neurologic condition; contraindications to measurements such as infection, menstruation, and allergy to nickel; other symptoms of PFD |
Thompson et al. study (37).
Thompson et al. study (38).
Abbreviations: NR: not reported; C: continent; I: incontinent; No. number; PFM: pelvic floor muscle; PFD: pelvic floor dysfunction; PFMT: pelvic floor muscle training; AbM: abdominal muscle; LBP: low back pain; HRT: hormone replacement therapy; DM: Diabetes mellitus; UI: urinary incontinence; POP: pelvic organ prolapse; CT: connective tissue; y: years; m: months; pp: postpartum; SUI: stress urinary incontinence; cm: centimeters; kg: kilograms; AHT: abdominal hypopressive technique; BMI: body mass index; cm: centimeters
Study characteristics related to population, co-activity, and assessed outcomes.
| Author | Instruction of co-activity | Maximal voluntary contraction (PFM) | Measurement of correct PFM contraction | Position tested | Measurement of contraction | PFMC Measurement and variable assessed | Muscles tested |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Bø et al. (27) | Activity of PFMs during TrA contraction. | NR | Inward lifting and squeezing of the pelvic openings and vaginal palpation. | Standing | US | Axial plane of minimal hiatal dimensions. Area measured as cm2. | PFMs |
| Tajiri et al. (22) | Recorded TrA during PFM contraction. | Yes | Verbal orientation | Supine | US | Not applicable | AbMs |
|
| |||||||
| Bø et al. (26) | Activity of the RA during PFM contraction. | Yes | Perineal and vaginal palpation; observation of movement and vaginal pressure measurements. | NR | EMG | Balloon catheters. Result specifications not described. | AbMs |
| Bø et al. (25) | Activity of PFMs during abdominal contraction. | NR | Vaginal palpation; observation and vaginal pressure measurements. | Supine | EMG | Needle EMG. Result specifications not described | PFMs |
| Sapsford et al. (6) | Activity of the TrA, RA, OI, OE and PFM was recorded during PFM contraction in three different lumbar spine positions. | Yes | Vaginal palpation. | Supine | EMG | Intravaginal probe using NEEN HealthCare. %MVC-normalized EMG amplitudes. | AbMs |
| Neuman et al. (33) | Activity of the TrA, OI, and PFM was recorded. The subjects performed PFM and abdominal contraction. | Yes | Perineal and vaginal palpation; observation of movement and vaginal pressure measurements. | Supine and standing | EMG | Vaginal surface EMG. %MVC-normalized EMG amplitudes. | PFMs and AbMs |
| Madill et al. (9) | Activity of the TrA, RA, OI, OE and PFM was recorded during PFM contraction. | Yes | Squeezing around the vagina and visible cephalad movement of the perineum, without breath holding. | Supine | EMG | Modified Femiscan™ EMG probe. %MVC-normalized EMG amplitudes. | AbMs |
| Thompson et al. (37) | Activity of the RA, OI, OE, and PFM was recorded during PFM contraction and valsalva. | Yes | Vaginal palpation. | Supine | EMG | Intravaginal probe Using NEEN HealthCare. %MVC-normalized EMG amplitudes. | PFMs and AbMs |
| Madill et al. (32) | Activity of the TrA, RA, OI, and OE was recorded during PFM contraction. | Yes | EMG and pressure and observation of the perineum. | Supine, sitting, and standing | EMG | Modified Femiscan™ EMG probe. %MVC-normalized EMG amplitudes. | AbMs |
| Junginger et al. (30) | Activity of the TrA and PFM was recorded during abdominal and PFM contraction. | No | Confirmed by EMG. | Supine | EMG | Intravaginal probe Periform®. %MVC-normalized EMG amplitudes. | PFMs and AbMs |
| Strupp et al. (35) | Activity of the TrA and PFM was recorded. The subjects performed AHT and PFM contraction. | Yes | Inspection and vaginal palpation. | Supine | EMG | Intravaginal probe Chattanooga Group®. MVEA-normalized EMG. | PFMs and AbMs |
| Chmielewska et al. (28) | Measurement of the TrA and RA during PFM contraction. | Yes | Confirmed by EMG. | Supine, sitting, and standing | EMG | Small diameter intravaginal probe. %MVC-normalized EMG amplitudes. | AbMs |
| Silva et al. (23) | Activity of the TrA/OI during PFM contraction. Activity of the PFM during TrA/OI contraction. | Yes | Vaginal palpation; orientation on how to effectively contract the PFMs | Standing | EMG | Endovaginal sensor PhysioMed Services®%. MVC-normalized EMG amplitudes. | PFMs and AbMs |
| Ithamar et al. (39) | Activity of the TrA/OI, RA, OE and PFM during AHT | Yes | Verbal orientation on how to effectively contract the PFMs | Supine, standing and quadrupedal | EMG | Intravaginal probe. %MVC-normalized EMG amplitudes. | PFMs |
|
| |||||||
| Devreese et al. (29) | PFMs during abdominal contraction. | NR | Inward observation of the perineum and vaginal palpation | Supine | Other | Digital palpation. Scoring system | PFMs |
| Thompson et al. (38) | Activity of the RA, OI, OE, and PFM was recorded during PFM contraction and the Valsalva maneuver. | NR | Vaginal palpation. | Supine | EMG | Intravaginal probe Using NEEN HealthCare. %MRC-normalized EMG amplitudes. | PFMs and AbMs |
| Madill et al. (31) | Activity of the RA, OI, and OE was recorded during PFM contraction. | Yes | Visible cephalad movement of the perineum. | Supine | EMG | Modified Femiscan™ EMG probe. RMS-MVC EMG amplitudes. | AbMs |
| Arab et al. (24) | Activity of the TrA and OI was recorded during PFM contraction. | Yes | Lifting of the bladder base on transabdominal US. | Not reported | US | Not applicable. | AbMs |
| Tajiri et al. (36) | TrA during PFM contraction. | Yes | NR | Supine | US | Not applicable | AbMs |
| Ptaszkowski et al. (34) | RA during PFM contraction. | Yes | Confirmed by the physiotherapist. | Standing | EMG | Life-care Vaginal Probe PR-02. RMS-MVC EMG amplitudes. | PFMs and AbMs |
Thompson et al. study (37).
Thompson et al. study (38).
Abbreviations: NR: not reported; AbM: abdominal muscle; PFM: pelvic floor muscle; TrA: transversus abdominis; RA: rectus abdominis; OI: obliquus internus abdominis; OE: obliquus externus abdominis; EMG: electromyography; US: ultrasonography; IAP: intra-abdominal pressure; MVC: maximal voluntary contraction; MRC: maximal reference contraction; MVEA: maximal voluntary electrical activity; RMS: root mean square.
Figure 2Risk of bias assessment. We considered “probably high risk of bias” as “definitely high risk of bias” (red color) and “probably low risk of bias” as “definitely low risk of bias” (green color).
Risk of bias assessment of the included studies.
| Author | Was the selection of exposed and nonexposed cohorts drawn from the same population? | Can we be confident in the assessment of exposure? | Can we be confident that the outcome of interest was not present at the start of the study? | Did the study match exposure and nonexposure for all variables that are associated with the outcome of interest or did the statistical analysis adjust for these prognostic variables? | Can we be confident in the assessment of the presence or absence of prognostic factors? | Can we be confident in the assessment of the outcome? | Was the follow-up of cohorts adequate? | Were co-interventions similar between groups? |
|---|---|---|---|---|---|---|---|---|
| Devreese et al. (29) | Definitely low risk | Probably low risk | Probably low risk | Probably high risk | Definitely low risk | Probably high risk | Definitely high risk | Probably high risk |
| Thompson et al. (38) | Probably high risk | Probably high risk | Probably low risk | Probably low risk | Definitely low risk | Probably high risk | Definitely high risk | Probably high risk |
| Madill et al. (31) | Probably low risk | Probably high risk | Probably low risk | Probably low risk | Definitely low risk | Definitely low risk | Definitely high risk | Probably high risk |
| Arab et al. (24) | Probably low risk | Probably low risk | Probably low risk | Probably low risk | Probably low risk | Probably high risk | Definitely high risk | Probably high risk |
| Tajiri et al. (36) | Probably high risk | Probably high risk | Probably low risk | Probably high risk | Definitely low risk | Probably high risk | Definitely high risk | Probably high risk |
| Ptaszkowski et al. (34) | Definitely low risk | Probably low risk | Probably low risk | Probably low risk | Definitely low risk | Probably high risk | Definitely high risk | Probably high risk |
Thompson et al. study (38).
Figure 3Forest plot showing the co-activity of the transversus abdominis, rectus abdominis, obliquus internus and obliquus externus muscles during maximal pelvic floor muscle contraction. CI = Confidence interval; PFD = Pelvic floor dysfunction.
Figure 4Sensitivity analysis of co-activity of transversus abdominis (without the Arab et al. 2011 study), rectus abdominis (without the Madill et al. (31)), obliquus internus (without the Madill et al. (31)) and obliquus externus (without the Madill et al. (31)) muscles when the pelvic floor muscles contract. CI = Confidence interval; PFD = Pelvic floor dysfunction.
GRADE evidence profile for cross-sectional studies: women without pelvic floor dysfunction versus women with pelvic floor dysfunction*.
| No. of participants (studies) | Quality assessment | Summary of findings | Certainty in estimates | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study event rates MD (SD) | Mean difference(95% CI) | Anticipated absolute effects | OR Quality of evidence | ||||||||
| Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Women without PFD | Women with PFD | Risk in women without PFD | Risk in women with PFD | |||
|
| |||||||||||
| 52 (2) | Serious limitation | Nonserious limitation | Serious limitation | Serious limitation | Undetectable | 2.5 (0.4) | 2.1 (0.3) | −0.61 (−1.42 to 0.20) | The mean rate of coactivity of the transversus abdominis muscles was 2.5. | The mean rate of coactivity of the transversus abdominis muscles in the exposed group was on average 0.61 lower (1.42 lower to 0.20 higher). | ⊕⊕OO LOW |
|
| |||||||||||
| 32 (1) | Serious limitation | Serious limitation | Serious limitation | Nonserious limitation | Undetectable | 2.5 (0.4) | 2.1 (0.3) | −1.02(−1.90 to -0.14) | The mean rate of coactivity of the transversus abdominis muscles was 2.5. | The mean rate of coactivity of the transversus abdominis muscles in the exposed group was on average 1.02 lower (1.9 lower to 0.14 lower). | ⊕OOO VERY LOW |
|
| |||||||||||
| 128 (3) | Serious limitation | Serious limitation | Serious limitation | Serious limitation | Undetectable | 6 (4) | 8 (5) | −2.05 (−6.51 to 2.42) | The mean rate of coactivity of the rectus abdominis muscle was 6. | The mean rate of coactivity of the rectus abdominis in the exposed group was on average 2.05 lower (6.51 lower to 2.42 higher). | ⊕OOO VERY LOW |
|
| |||||||||||
| 56 (2) | Serious limitation | Serious limitation | Serious limitation | Nonserious limitation | Undetectable | 6 (4) | 8 (5) | 0.89 (-0.03 to 1.82) | The mean rate of coactivity of the rectus abdominis muscle was 6. | The mean rate of coactivity of the rectus abdominis in the exposed group was on average 0.89 higher (0.03 higher to 1.82 higher). | ⊕⊕OO LOW |
|
| |||||||||||
| 118 (3) | Serious limitation | Serious limitation | Serious limitation | Serious limitation | Undetectable | 23 (3) | 18 (2) | −0.47 (−2.38 to 1.44) | The mean rate of coactivity of the obliquus internus muscle was 0.23 | The mean rate of coactivity of the obliquus internus in the exposed group was on average 0.47 lower (2.38 lower to 1.44 higher). | ⊕OOO VERY LOW |
|
| |||||||||||
| 26 (1) | Serious limitation | Serious limitation | Serious limitation | Nonserious limitation | Undetectable | 26 (18) | 57 (34) | 1.10 (0.27 to 1.94) | The mean rate of coactivity of the obliquus internus muscle was 26. | The mean rate of coactivity of the obliquus internus in the exposed group was on average 1.10 higher (0.27 higher to 1.94 higher). | ⊕⊕OO LOW |
|
| |||||||||||
| 98 (2) | Serious limitation | Serious limitation | Serious limitation | Serious limitation | Undetectable | 30 (5) | 21 (4) | 0.01 (−4.00 to 4.03) | The mean rate of coactivity of the obliquus externus muscle was 30. | The mean rate of coactivity of the obliquus externus in the exposed group was on average 0.01 higher (4.00 lower to 4.03 higher). | ⊕OOO VERY LOW |
|
| |||||||||||
| 26 (1) | Serious limitation | Serious limitation | Serious limitation | Nonserious limitation | Undetectable | 9 (4) | 37 (18) | 2.08 (1.10 to 3.06) | The mean rate of coactivity of the obliquus externus muscle was 9. | The mean rate of coactivity of the obliquus externus in the exposed group was on average 2.08 higher (1.10 higher to 3.06 higher). | ⊕⊕OO LOW |
Abbreviations: MD: mean difference; SD: standard deviation; PFD: pelvic floor dysfunction; CI: Confidence interval.
Cross-sectional studies started from high quality evidence because of the nature of the clinical question.
The estimated risk control was taken from the mean estimated control risk from the Tajiri (2011) study (35).
The estimated risk control was taken from the mean estimated control risk from the Thompson (2006b) study (37).
The estimated risk control was taken from the mean estimated control risk from the Madill (2009) study (30).
Issues related to exposure and outcome assessments, follow-up period and cointerventions.
There may not be considerable heterogeneity (I2 <50%).
There is considerable heterogeneity (I2>75%).
Included studies with only one PFD.
95% Confidence interval for absolute effects include clinically important significance and no significance.
Search strategy.
| (Women OR woman OR female OR Women’s Groups OR Women’s Group OR Women Groups OR Women Group OR healthy women OR healthy woman OR incontinent OR incontinent women OR incontinent woman OR urinary incontinence in women OR Female Urinary Incontinence OR continent OR continent women OR continent woman OR urgency urinary incontinence OR Urinary Stress Incontinence OR stress urinary incontinence OR stress urinary OR UUI OR SUI OR MUI OR Urinary Urge Incontinence OR Urinary Reflex Incontinence OR Urge Incontinence OR mixed urinary incontinence OR Urinary Bladder Disease OR Urinary Bladder Diseases OR Urinary Reflex Incontinence) AND ((Pelvic Floor OR Pelvic Diaphragm OR Pelvic Diaphragms OR Pelvic Floor Disorders OR Pelvic Floor Disorder OR Pelvic Floor Disease OR Pelvic Floor Diseases OR pelvic floor dysfunction OR pelvic floor dysfunctions OR Pelvic Floor muscle OR Pelvic Floor muscles OR Urinary Incontinence OR abdomino-pelvic musculature OR perineal musculature OR Perineum OR perineums OR perineal function OR pelvic floor contraction OR pelvic floor muscle contractions OR co-contraction OR muscle synergism OR muscle co-contraction OR co-activity OR co-activity muscle) AND (Abdominal Muscles OR Abdominal Muscle OR Abdomen OR Abdomens OR abdomino-pelvic musculature OR transversus abdominis OR Rectus Abdominis OR Rectus Muscle of Abdomen OR Abdomen Rectus Muscle OR Abdomen Rectus Muscles OR external obliques OR external oblique OR internal obliques OR internal oblique OR abdominal muscle contractions OR synergistic co-contraction of abdominal muscles OR synergism co-contraction of abdominal muscles OR co-contraction OR muscle synergism OR muscle co-contraction OR co-activity OR co-activity muscle)) |